Are there specific dates for the yervoy discount?

When Does Yervoy Go Off-Patent, and What Does It Mean for Discounts?

Yervoy (ipilimumab) is a medication used to treat certain types of skin cancer. The patent protection for Yervoy is set to expire on October 16, 2024 [1]. However, the actual discount for the medication might not kick in immediately.

Why Do Patent Expiration Dates Matter for Discounts?

When a patent expires, generic versions of the medication can start being manufactured and sold, often at a lower price. However, drug companies may still have exclusive rights to certain forms of the medication or related products.

How Will Discounts for Yervoy Work After the Patent Expires?

The discount for Yervoy might be in the form of biosimilars, which are similar but not identical versions of the original medication. Companies like Biocon, Gilead Sciences, and Eli Lilly are working on biosimilars for Yervoy, which could become available in 2025 or later [2].

Will Insurers Cover Biosimilars?

Biosimilars are expected to have a similar price point to generic versions of other medications. However, insurance coverage may vary depending on the specific biosimilar and the patient's insurance plan. Patients should check with their insurers to see if biosimilars are covered and what the copayment would be.

Who Will Benefit from the Discounts?

Discounts on Yervoy could benefit patients who are currently taking the medication for skin cancer. Patients should discuss their treatment options with their healthcare provider, including the possibility of switching to a biosimilar or a generic version of the medication.

References:

[1] DrugPatentWatch.com: Patent expiration date for Yervoy.
[2] Biocon, Gilead Sciences, and Eli Lilly are working on biosimilars for Yervoy: Details of biosimilar development for Yervoy.